PTO/SB/05 (03-

Please type a plus sign (+) inside this box

Approved for use through 10/31/2002, OMB 0651-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

UTILITY PATENT APPLICATION TRANSMITTAL

1122 Attorney Docket No. Li Chen, et al. First Inventor DIAMINOTHIAZOLES HAVING ANTIPROLIFERATIVE ACTIVITY

EL912161906US Express Mail Label No. (Only for new nonprovisional applications under 37 CFR 1.53(b)) Commissioner for Patents **APPLICATION ELEMENTS** ADDRESS TO: Box Patent Application Washington, DC 20231 See MPEP chapter 600 concerning utility patent application contents. Fee Transmittal Form (e.g., PTO/SB/17) CD-ROM or CD-R in duplicate, large table or (Submit an original and a duplicate Computer Program (Appendix) Applicant claims small entity status. 8. Nucleotide and/or Amino Acid Sequence Submission See 37 CFR 1.27. (if applicable, all necessary) specification [Total Pages 173] 3. X Computer Readable Form (CRF) - Descriptive title of the invention Specification Sequence Listing on: - Cross Reference to Related Applications i. D CD-ROM or CD-R (2 copies); or - Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, ii. 🔲 paper or a computer program listing appendix - Background of the Invention Statements verifying identity of above copies - Brief Summary of the Invention ACCOMPANYING APPLICATION PARTS - Brief Description of the Drawings (if filed) - Detailed Description Assignment Papers (cover sheet & document(s)) - Claim(s) Power of 37 CFR 3.73(b) Statement - Abstract of the Disclosure Attorney (when there is an assignee) English Translation Document (if applicable) Drawing(s) (35 U.S.C. 113) [Total Sheets Copies of IDS Information Disclosure [Total Pages Citations 5. Oath or Declaration Statement (IDS)/PTO-1449 **Preliminary Amendment** X Newly executed (original or copy)
Copy from a prior application (37 CFR 1.63 (d))
(for continuationIdivisional with Box 18 completed) Return Receipt Postcard (MPEP 503) (Should be specifically itemized) Certified Copy of Priority Document(s) (if foreign priority is claimed) **DELETION OF INVENTOR(S)** Signed statement attached deleting inventor(s) Nonpublication Request under 35 U.S.C. 122 named in the prior application, see 37 CFR (b)(2)(B)(i). Applicant must attach form PTO/SB/35 1.63(d)(2) and 1.33(b). or its equivalent. 6. X Application Data Sheet. See 37 CFR 1.76 Other: 18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: Continuation Divisional Continuation-in-part (CIP) of prior application No.:_ Group Art Unit: For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts 19. CORRESPONDENCE ADDRESS × 00151 Customer Number or Bar Code Label Name <u>Address</u> State Zip Code City Fax Country Telephone Patricia S. Rocha-Tramaloni 31054 Registration No. (Attorney/Agent) Name (Print/Type) 1/9/2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

Date

Signature

Commissioner for Patents BOX PATENT APPLICATION Washington, D.C. 20231 Hoffmann-La Roche Inc. 340 Kingsland Street
Nutley, NJ 07110
Case Docket 1122
January 9, 2002

Sir:

Transmitted herewith for filing under 37 C.F.R. § 1.53(b) is the patent application of

Inventors:

Li Chen, Qingjie Ding, Paul Gillespie, Kyungjin Kim, Allen John Lovey,

Warren William McComas, John Guilfoyle Mullin, Jr., Agostino Perrotta

For: DIAMINOTHIAZOLES HAVING ANTIPROLIFERATIVE ACTIVITY

1. The fee has been calculated as shown below:

NO. FILED	NO. EXTRA	RATE	FEE	
64 - 20	44	x \$18	792.00	
14 - 3	11	x \$84	924.00	
INDEP. CLAIMS 14-3 11 MULTIPLE DEPENDENT CLAIMS PRESENTED				
BASIC FEE \$ 740.00				
TOTAL \$2456.00				
	64 - 20 14 - 3	64 - 20 44 14 - 3 11 PENDENT CLAIMS PRESENTED	64 - 20	

Please charge Deposit Account No. 08-2525 in the amount noted above.

The Commissioner is hereby authorized to charge payment of any additional fees associated with this communication or credit any overpayment to Deposit Account No. 08-2525, including those under 37 C.F.R. § 1.16 and 1.17. This sheet is provided in duplicate.

Continue to address all communications to:

George W. Johnston Hoffmann-La Roche Inc. 340 Kingsland Street Nutley, NJ 07110

Attorney for Applicants
Patricia S. Rocha-Tramaloni
(Rec. No. 21054)

(Reg. No. 31054)

116619

DEPOSIT ACCOUNT NO. 03-2525

OUR ORDER NO. 4/0

U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Certification under 37 CFR 1.10

I hereby certify that this form and all documents cited on this form are being deposited with the United States Postal Service in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number:

EL912161906 US

addressed to:

Commissioner for Patents Washington, D.C. 20231

on January 9, 2002

Pamela Johnston

Typed or printed name of person of signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Papers Submitted for Case Docket 1122 US: Patent Application Transmittal Form, Application Data Sheet, Fee Transmittal Form, Specification - 173 pgs., Declaration - 5 pgs.